Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | 22 Parkinson's trials, 3 stopped | 0.89 |
| literature PubMed | 16 Parkinson's papers of 2,015 | 0.63 |
| pathways Reactome | 2 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 6411
Sealed predictions
- AIM2 in dopamine neurons, braak-0.32 (p 0.407) → +0.45 (p 0.227)receipt 6418
Swarm cases
receipt 6418: AIM2 in dopamine neurons, braak
- power
- full sample +0.12 (p 0.640, n 18), 95% CI -0.37 to +0.55. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.14 (p 0.591, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.09 (p 0.715, n 18). could be the mix.
- skeptic
- leave-one-out range -0.01 to +0.23, sign flips 1; without severely affected donors +0.12 (p 0.640, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for AIM2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts